Sequencing genomes to diagnose puzzling symptoms presents a conundrum: how to interpret whether a persons genotype causes the syndrome without comparison to many other human genome sequences? Put another way, a gene variant (mutation) that people with the same symptoms share must also be absent in people without the syndrome for it to be labeled causal, rather than the disturbingly vague variant of uncertain significance.
The challenge is in de-identifying the hordes of healthy genomes needed to add diagnostic context to those with disease-causing mutations. A team of biologists, computer scientists, and cryptographers at Stanford University described in Sciencemagazine a new computational tool to make certain that genomic discrimination doesnt happen, according to co-author Gill Bejerano, PhD, associate professor of developmental biology, pediatrics, and computer science.
A genome sequence can reveal much more than the needle-in-the-haystack mutations that might underlie a diagnosis: parentage, ancestry, susceptibilities and risk factors, even whether a certain drug will work, binge-drinking make you violently ill, or smoking likely to cause lung cancer. How can genome sequencing provide useful information without sacrificing privacy?
THE CLASSIC GYMREK STUDY
One of my favorite papers is also from Science, Identifying Personal Genomes by Surname Inference,if you can call a report from 2013 a classic. First author was then-grad student Melissa Gymrek, who now heads a lab at UCSD.
Gymrek and her co-workers tackled the 1000 Genomes Project, which ran from 2008-2015 and spawned a supposedly anonymous database. The informed consent form read, . . . it will be hard for anyone to find out anything about you personally from any of this research.
Right. Online searches easily shattered that premature promise of privacy.
Gymrek, then a student of Yaniv Erlich, a researcher at the Whitehead Institute who had worked with databases at financial banks, tried to identify people whod anonymously donated DNA to the 1000 Genomes Projectjust to see if they could.
They looked at sets of short tandem repeats, the bits of sequence of 2-13 DNA bases used in forensics and genetic genealogy to distinguish individuals. Consulting public genealogy databases they found surnames corresponding to specific Y haplotypes (STRs linked on the male chromosome).
Basic public information such as state of residence and birth year was easy to find. DNA data posted on family websites confirmed some identifications. The researchers found women by cross-referencing DNA sequences in the Coriell Cell Repositories in New Jersey to other data. Searching mutation databases for disease, hometown, and date of birth identified children.
When Gymrek had identified 50 people fairly easily, Dr. Erlich, alarmed, notified the NIH, catalyzing efforts to begin to hide some of the DNA data, although of course they couldnt control people whod post anything on social media. Their report in Science became a rallying cry of sorts for the ease of assigning names to DNA sequences something thats much easier today, with more than a million of our genomes sequenced and with the ability to carry such information on our smartphones.
THREE COMPELLING EXAMPLES
In the new paper, the researchers used a cryptographic approach called Yaos protocol with cloud computing to enable a genome peruser to zero in on the DNA sequences of clinical interest, while ignoring all else. Its a genomic cloaking device, for those familiar with the Romulan invention from Star Trek that makes a spaceship seem to vanish. It irked Captain Kirk.
Aterrific news releaseby Krista Conger at Stanford explained it all:
Using the technique, the researchers were able to identify the responsible gene mutations in groups of patients with four rare diseases; pinpoint the likely culprit of a genetic disease in a baby by comparing his DNA with that of his parents; and determine which out of hundreds of patients at two individual medical centers with similar symptoms also shared gene mutations. They did this all while keeping 97 percent or more of the participants unique genetic information completely hidden from anyone other than the individuals themselves, the release said.
Many news aggregators just publish news releases verbatim, but I dug a little deeper:
For the four already-known diseases, the technique identified 211-374 rare functional gene variants in 210- 356 genes (meaning more than one mutation in some genes) among the patients, then selected the most likely candidates. The computation correctly identified the mutation in all four across all 20,663 genes, and in 5 to 10 seconds. Anyone who reads this blog regularly knows that a diagnostic odysseyfor a rare genetic disease can take years, using conventional medicine.
The baby was XY (chromosomally male) with female genitalia. The child and the parents each had 164-185 rare functional variants found with exome sequencing, and the computation revealed only two unique to the child. A review of the genetics literature found that one, ACTB, made sense and it had been found in the 1000 Genomes Project! Only the two meaningful variants were reported to the parents and their provider, leaving what the researchers call a protection quotient of 99.6%. (Definition: the fraction of private information that is exposed neither to the other participants nor to the entity running the computation.)This more complex test took just under an hour.
The researchers compared 928 patients from one medical center to 282 patients at another, generating a list of 5,000+ rare functional variants seen in at least one patient, then whittled it down to 159 variants seen among patients in both hospitals. The info diagnosed patients with specific heart problems, and also revealed previously unrecognized gene-disease connections so the computation is a discovery tool too.
BENEFITS TO GENOME CLOAKING
The beauty of the technique, and the secret to the privacy promise, is that the patient enters the data, into smartphone, tablet, or computer. That shouldnt sound scary, for we send our info into the ether all the time, from ordering concert tickets to making plane reservations. In this way, no person or computer, other than the individuals themselves, has access to the complete set of genetic information, said Dr. Bejerano.
The computation encrypts a genome sequence into a linear series of values that rates each gene variant according to several criteria well-established among genome researchers:
Could the genes function explain a patients symptoms?
Is the variant rare? This is where the need for a backup million or so sequenced genomes comes in. If a variant is common, it cant be making people too sick to reproduce.
Is the variant functional? What does it do?
The direct involvement of the patient and the return of only relevant data from the cloud can avoid the genetic red flags that might underlie denial of a loan or life insurance, neither protected under the Genetic Information Nondiscrimination Act (GINA), should it survive the Trump administration. And the data from the healthy genomes is aggregated without identifiers.
Genome cloaking at some point requires interpretation of and communication by health care providers who are familiar and comfortable with DNA information. That might still be a rare breed. Heres a quick test that I just invented for a provider discussing genetic testing: define SNP, CNV, VUS, and exome. If she or he cant, find a genetic counselorpronto. The medias common depiction of physicians as scientists the Dana Scully effect, from the X-Files doctor constantly calling herself a scientist can set up unrealistic expectations of expertise.
Another advance that could come from genome cloaking would be, finally, the ability to track sets of genes. This is important because gene actions can oppose. Whats the use of finding out you have a gene variant that increases the risk of Alzheimers, like APOE e4, yet not knowing that you also inherited a gene variant that lowers the risk (APOE e2)?
With the ability to nail disease-causing gene variants, while offering the privacy that Melissa Gymreck showed years ago to be easily compromised, genome cloaking may be able to catapult DNA science into the research lab and clinic, by providing reassurance to both families with genetic disease and to the healthy population whose genome sequences are vital to providing context.
(Thanks to NHGRI for images.)
Read the original here:
Genome Cloaking Preserves Privacy While Enabling Diagnosis ... - PLoS Blogs (blog)
- BENITEC BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - February 13th, 2023 [February 13th, 2023]
- CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day - Marketscreener.com - February 7th, 2023 [February 7th, 2023]
- Gene | Definition, Structure, Expression, & Facts | Britannica - January 27th, 2023 [January 27th, 2023]
- New gene therapy delivers treatment directly to brain - January 27th, 2023 [January 27th, 2023]
- Indian Pharma Congress: Gene-cell therapy, preventive medicine future of health care, says expert - Economic Times - January 25th, 2023 [January 25th, 2023]
- A blood test that identifies people at higher risk of miscarriage? Thats the goal of this award-winning Rutgers med student. - The Philadelphia... - January 19th, 2023 [January 19th, 2023]
- Gene Therapy: Genes As Medicine | Pfizer - January 6th, 2023 [January 6th, 2023]
- How Genomics will ensure a risk-free and beneficial treatment for good health and well-being - The Financial Express - December 28th, 2022 [December 28th, 2022]
- Regenerative Medicine Advanced Therapy Designation | FDA - December 18th, 2022 [December 18th, 2022]
- 3576 - Gene ResultCXCL8 C-X-C motif chemokine ligand 8 [ (human)] - November 23rd, 2022 [November 23rd, 2022]
- Study identifies new gene that drives colon cancer - EurekAlert - October 17th, 2022 [October 17th, 2022]
- Updated Stroke Gene Panels: Rapid evolution of knowledge on monogenic causes of stroke | European Journal of Human Genetics - Nature.com - October 17th, 2022 [October 17th, 2022]
- The challenges of translating CRISPR to the clinic - Labiotech.eu - October 17th, 2022 [October 17th, 2022]
- Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene... - October 17th, 2022 [October 17th, 2022]
- 'We have to find a way': FDA seeks solutions to aid bespoke gene therapy - BioPharma Dive - October 17th, 2022 [October 17th, 2022]
- Mathematical model could bring us closer to effective stem cell therapies - Michigan Medicine - October 17th, 2022 [October 17th, 2022]
- Approval, Commercialization Highlighted at Cell & Gene Meeting on the Mesa - Genetic Engineering & Biotechnology News - October 17th, 2022 [October 17th, 2022]
- CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual... - October 17th, 2022 [October 17th, 2022]
- Depression Treatment: How Genetic Testing Can Help Find the Right Medication - Dunya News - October 17th, 2022 [October 17th, 2022]
- The Risk-Reward Proposition for CGT Clinical Trials - Applied Clinical Trials Online - October 17th, 2022 [October 17th, 2022]
- Precision Medicine Could Get Even More Precise With Allarity Therapeutics Next-Generation Diagnostics - Benzinga - October 17th, 2022 [October 17th, 2022]
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 17th, 2022 [October 17th, 2022]
- Time for your medicine: unlocking the power of our body clocks - The Guardian - October 17th, 2022 [October 17th, 2022]
- Replay establishes distinguished Scientific Advisory Board of genomic medicine and cell therapy experts - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- Scientists Reappraise the Role of Zombie Cells That Anti-aging Medicine Has Sought to Eliminate - Neuroscience News - October 17th, 2022 [October 17th, 2022]
- Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease - Business... - October 17th, 2022 [October 17th, 2022]
- Gene Expression Signatures Are Analyzed for Biomarkers of Response in HCC - Targeted Oncology - October 17th, 2022 [October 17th, 2022]
- NHS England World-first national genetic testing service to deliver rapid life-saving checks for babies and kids - NHS England - October 17th, 2022 [October 17th, 2022]
- The proteinprotein relationship that could mend a broken heart - RegMedNet - October 17th, 2022 [October 17th, 2022]
- Study finds microprotein correlated to Alzheimers risk - Daily Trojan Online - October 11th, 2022 [October 11th, 2022]
- Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer - Yahoo Finance - October 11th, 2022 [October 11th, 2022]
- Gene Therapy Rapidly Improves Night Vision in Adults with Congenital Blindness - Newswise - October 11th, 2022 [October 11th, 2022]
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- The Pros and Cons of Lentiviral and Adeno-Associated Viral Vectors - The Medicine Maker - October 11th, 2022 [October 11th, 2022]
- Insights & Outcomes: Foreign DNA, quantum potholes and relapsing fever - Yale News - October 11th, 2022 [October 11th, 2022]
- Expediting IND applications with drug master files - BioPharma Dive - October 11th, 2022 [October 11th, 2022]
- UNC School of Medicine Awarded $3 Million to Lead Study to Reduce PTSD Frequency, Severity | Newsroom - UNC Health and UNC School of Medicine - October 11th, 2022 [October 11th, 2022]
- Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa - businesswire.com - October 8th, 2022 [October 8th, 2022]
- The Next Crispr Gene Editing IPO Could Be Near - Henry Herald - October 8th, 2022 [October 8th, 2022]
- 10-year CRISPR anniversary: How gene editing revolutionized medicine, and what lies ahead - Genetic Literacy Project - October 8th, 2022 [October 8th, 2022]
- Blood from a baby at birth can be gene sequenced to prevent diseases - USA TODAY - October 8th, 2022 [October 8th, 2022]
- What doctors wish patients knew about breast-cancer prevention - American Medical Association - October 8th, 2022 [October 8th, 2022]
- Growth in Cell and Gene Therapy Market - Pharmaceutical Technology Magazine - October 8th, 2022 [October 8th, 2022]
- Gene Editing Service Market 2022 : Top Players to Reflect Impressive Growth Rate till 2029: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA,... - October 8th, 2022 [October 8th, 2022]
- Tip Sheet: $78 million to support new precision oncology institute, update on experimental gene therapy for herpes and the launch of Fred Hutch's new... - October 8th, 2022 [October 8th, 2022]
- Cell and Gene Therapy: Rewriting the Future of Medicine - Technology Networks - October 2nd, 2022 [October 2nd, 2022]
- Growth in Cell and Gene Therapy Market - BioPharm International - October 2nd, 2022 [October 2nd, 2022]
- CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130 for the Treatment of Cutaneous T-Cell... - October 2nd, 2022 [October 2nd, 2022]
- BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA - PR... - October 2nd, 2022 [October 2nd, 2022]
- Fighting Breast and Ovarian Cancer With a Lupus Antibody - Yale School of Medicine - October 2nd, 2022 [October 2nd, 2022]
- This gene therapy company is testing new tech to 'switch off' diabetes and obesity with a pill - Euronews - October 2nd, 2022 [October 2nd, 2022]
- Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Societys 2022 Scientific Sessions - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Risk of Alzheimer's dementia may be predicted with help of new tool Washington University School of Medicine in St. Louis - Washington University... - October 2nd, 2022 [October 2nd, 2022]
- Tiny Sea Creature's Genes Shed Light on Evolution of Immunity - UPMC - October 2nd, 2022 [October 2nd, 2022]
- Who will get the call from Stockholm? It's time for STAT's 2022 Nobel Prize predictions - STAT - October 2nd, 2022 [October 2nd, 2022]
- Excision BioTherapeutics Awarded California Institute for Regenerative Medicine (CIRM) Grant to Support Ongoing Phase 1/2 Trial Evaluating EBT-101 as... - October 2nd, 2022 [October 2nd, 2022]
- NeuroVoices: Emma Ciafaloni, MD, on the Vast Expansion of Innovative Approaches to Duchenne Muscular Dystrophy - Neurology Live - October 2nd, 2022 [October 2nd, 2022]
- COVID mRNA Jabs and Testing Kicked Off This Industry of Drug Development: Here's What You Need to Know - The Epoch Times - October 2nd, 2022 [October 2nd, 2022]
- Kidney resident macrophages have distinct subpopulations and occupy distinct microenvironments - University of Alabama at Birmingham - October 2nd, 2022 [October 2nd, 2022]
- Nobel Prize for medicine: the full list of winners - The National - October 2nd, 2022 [October 2nd, 2022]
- The surprising link between circadian disruption and cancer may have to do with temperature - EurekAlert - October 2nd, 2022 [October 2nd, 2022]
- The global live cell imaging market is expected to grow at a CAGR of 8.44% during 2022-2027 - Yahoo Finance - October 2nd, 2022 [October 2nd, 2022]
- Chroma Medicine Announces Formation of Scientific Advisory Board of Global Experts in Gene Editing and Cell and Gene Therapy - PR Newswire - September 20th, 2022 [September 20th, 2022]
- Ring Therapeutics Announces Issuance of U.S. Patent for its Anellovector Compositions - Yahoo Finance - September 20th, 2022 [September 20th, 2022]
- Cholesterol gene mutation: Why would a healthy 27-year-old have severe heart problems? - 69News WFMZ-TV - September 20th, 2022 [September 20th, 2022]
- Gene Therapy for Severe Hemophilia B Could Be More Cost Effective Than Current Treatments - Managed Healthcare Executive - September 20th, 2022 [September 20th, 2022]
- AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis... - September 20th, 2022 [September 20th, 2022]
- The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List - The Medicine Maker - September 20th, 2022 [September 20th, 2022]
- Leading Virus Researcher to Chair UVA's Department of Microbiology, Immunology and Cancer Biology - UVA Health Newsroom - September 20th, 2022 [September 20th, 2022]
- Work remains on Tay-Sachs and other Ashkenazi genetic disorders J. - The Jewish News of Northern California - September 20th, 2022 [September 20th, 2022]
- Study Shows Genetic Link to Moving to the Beat of Music - Newswise - September 20th, 2022 [September 20th, 2022]
- Viewpoint: In the post Roe v Wade world, what changes should a biology textbook writer make to address the medical repercussions of Dobbs? - Genetic... - September 20th, 2022 [September 20th, 2022]
- Alnylam Receives Approval in Europe for AMVUTTRA (vutrisiran) for the Treatment of Hereditary Transthyretin-mediated (hATTR) Amyloidosis in Adult... - September 20th, 2022 [September 20th, 2022]
- CSL flexes gene therapy muscle with latest drug - Sydney Morning Herald - September 20th, 2022 [September 20th, 2022]
- The MIT Press releases new book on the science of the heart from cardiac expert Dr. Sian Harding - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo... - September 20th, 2022 [September 20th, 2022]
- Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801... - September 20th, 2022 [September 20th, 2022]
- Do You Have Lung Cancer With An EGFR Mutation? If So, The Drug Tagrisso Might Be Right For You Based On New Results From A 'Practice Changing' Trial -... - September 20th, 2022 [September 20th, 2022]
- Getting rid of unwanted transformed cells: Possible new directions in cancer therapy - EurekAlert - September 20th, 2022 [September 20th, 2022]
- Sven Kili on reconvening with the ISCT - The Medicine Maker - September 14th, 2022 [September 14th, 2022]